GlaxoSmithKline is a large global corporation. The supply chain is very complex involving 107 factories, 350 contract sites, 160 different markets, 1200 different brands and circa 36,000 finished packs per year.

Optimising the levels of inventory and the nodes where it should be held is key to providing a supply chain that is truly competitive for GSK. It will:
    - Reduce waste and write offs
    - Reduce the need for warehousing
    - Release capital

GSK took the decision to buy 'SmartOps', a strategic modelling tool that is used to optimise inventory in a global arena. Dr Sridhar Tayur, founder and CEO for SmartOps, delivered the following presentation as an educational session for employees who will work with the SmartOps solution in the future.

To enlarge the video or play full screen, right click over the video image and select the appropriate option.